National Institute for Health and Care

Excellence
Final

Abortion care
[E] VTE prophylaxis for women having abortion

NICE guideline NG140

Evidence reviews
September 2019

Final

These evidence reviews were developed

by the National Guideline Alliance hosted
by the Royal College of Obstetricians and
Gynaecologists
FINAL

Disclaimer
The recommendations in this guideline represent the view of NICE, arrived at after careful
consideration of the evidence available. When exercising their judgement, professionals are
expected to take this guideline fully into account, alongside the individual needs, preferences
and values of their patients or service users. The recommendations in this guideline are not
mandatory and the guideline does not override the responsibility of healthcare professionals
to make decisions appropriate to the circumstances of the individual patient, in consultation
with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be
applied when individual health professionals and their patients or service users wish to use it.
They should do so in the context of local and national priorities for funding and developing
services, and in light of their duties to have due regard to the need to eliminate unlawful
discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing
in this guideline should be interpreted in a way that would be inconsistent with compliance
with those duties.
NICE guidelines cover health and care in England. Decisions on how they apply in other UK
countries are made by ministers in the Welsh Government, Scottish Government, and
Northern Ireland Executive. All NICE guidance is subject to regular review and may be
updated or withdrawn.

Copyright
© NICE 2019. All rights reserved. Subject to Notice of Rights.

ISBN:978-1-4731-3539-0
FINAL

Contents
Contents .............................................................................................................................. 4
VTE prophylaxis for women having abortion .................................................................... 6
Review question ............................................................................................................. 6
Introduction ........................................................................................................... 6
PICO table............................................................................................................. 6
Clinical evidence ................................................................................................... 7
Summary of clinical studies included in the evidence review ................................. 7
Quality assessment of clinical studies included in the evidence review ................. 7
Economic evidence ............................................................................................... 7
Economic model .................................................................................................... 7
Resource impact ................................................................................................... 8
Evidence statements ............................................................................................. 8
The committee’s discussion of the evidence.......................................................... 8
References .......................................................................................................... 10
Appendices ........................................................................................................................ 11
Appendix A – Review protocols .................................................................................... 11
Review protocol for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis? ................................................................... 11
Appendix B – Literature search strategies .................................................................... 15
Literature search strategy for review question: In women who are undergoing
an abortion up to 24 weeks’ gestation, and who are identified as
requiring pharmacological thromboprophylaxis, what is the optimal
timing and duration of VTE prophylaxis? .................................................. 15
Appendix C – Clinical evidence study selection ............................................................ 18
Clinical evidence study selection for review question: In women who are
undergoing an abortion up to 24 weeks’ gestation, and who are
identified as requiring pharmacological thromboprophylaxis, what is the
optimal timing and duration of VTE prophylaxis?...................................... 18
Appendix D – Clinical evidence tables .......................................................................... 19
Clinical evidence tables for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis? ................................................................... 19
Appendix E – Forest plots............................................................................................. 19
Forest plots for review question: In women who are undergoing an abortion up
to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis? ................................................................... 19
Appendix F – GRADE tables ........................................................................................ 19
GRADE tables for review question: In women who are undergoing an abortion
up to 24 weeks’ gestation, and who are identified as requiring

4
FINAL

pharmacological thromboprophylaxis, what is the optimal timing and

duration of VTE prophylaxis? ................................................................... 19
Appendix G – Economic evidence study selection ........................................................ 19
Economic evidence for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis? ................................................................... 19
Appendix H – Economic evidence tables ...................................................................... 19
Economic evidence tables for review question: In women who are undergoing
an abortion up to 24 weeks’ gestation, and who are identified as
requiring pharmacological thromboprophylaxis, what is the optimal
timing and duration of VTE prophylaxis? .................................................. 19
Appendix I –Economic evidence profiles ...................................................................... 19
Economic evidence profiles for review question: In women who are
undergoing an abortion up to 24 weeks’ gestation, and who are
identified as requiring pharmacological thromboprophylaxis, what is the
optimal timing and duration of VTE prophylaxis?...................................... 19
Appendix J –Economic analysis ................................................................................... 20
Economic analysis for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis? ................................................................... 20
Appendix K – Excluded studies .................................................................................... 21
Excluded studies for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis? ................................................................... 21
Clinical studies .................................................................................................... 21
Economic studies ................................................................................................ 21
Appendix L – Research recommendations ................................................................... 22
Research recommendations for review question: In women who are
undergoing an abortion up to 24 weeks’ gestation, and who are
identified as requiring pharmacological thromboprophylaxis, what is the
optimal timing and duration of VTE prophylaxis?...................................... 22

5
 FINAL

VTE prophylaxis for women having

abortion
Review question
In women who are undergoing an abortion up to 24 weeks’ gestation, and who are
identified as requiring pharmacological thromboprophylaxis, what is the optimal
timing and duration of VTE prophylaxis?

Introduction
The aim of this review is to determine the optimal duration and timing of
pharmacological thromboprophylaxis for women having an abortion up to 24 weeks’
gestation who are at risk of venous thromboembolism (VTE).
At the time of development, the title of this guideline was ‘Termination of pregnancy’
and this term was used throughout the guideline. In response to comments from
stakeholders, the title was changed to ‘Abortion care’ and abortion has been used
throughout. Therefore, both terms appear in this evidence report.

PICO table
See Table 1 for a summary of the population, intervention, comparison and outcome
(PICO) characteristics of this review.

Table 1: Summary of the protocol (PICO table)

Population Women who are having a surgical or medical termination of
pregnancy up to 24 weeks’ gestation and have been identified as
requiring pharmacological thromboprophylaxis
Intervention • Low molecular weight heparin
• Direct oral anti coagulants
Comparison • Low molecular weight heparin started at time A for duration A
• Low molecular weight heparin started at time A for duration B
• Low molecular weight heparin started at time B for duration A
• Low molecular weight heparin started at time B for duration B
• Low molecular weight heparin (any start time and duration)
versus direct oral anti coagulants (any start time and duration)
Outcome Critical outcomes:
• Cardiovascular mortality within 6 weeks of termination
• Major bleeding for the duration of low molecular weight heparin
(as defined by the International Society on Thrombosis and
Haemostasis bleeding scale)
• Fatal pulmonary embolism within 6 weeks of termination

Important outcomes:
• Symptomatic deep vein thrombosis within 6 weeks of
termination
• Pulmonary embolism within 6 weeks of termination

6
 FINAL

• Clinically relevant minor bleeding for the duration of low

molecular weight heparin (as defined by the International
Society on Thrombosis and Haemostasis bleeding scale)
• Patient satisfaction

For further details see the full review protocol in appendix A.

Clinical evidence

Included studies
Only studies conducted from 1995 onwards were considered for this review question,
as low molecular weight heparin was not available until 1995 and the first direct oral
anticoagulants were approved in 2008.
A systematic review of the clinical literature was conducted but no studies were
identified which were applicable to this review question.
See the literature search strategy in appendix B and the study selection flow chart in
appendix C.

Excluded studies
Studies not included in this review with reasons for their exclusions are provided in
appendix K.

Summary of clinical studies included in the evidence review

No studies were identified which were applicable to this review question (and so
there are no evidence tables in Appendix D). No meta-analysis was undertaken for
this review (and so there are no forest plots in Appendix E).

Quality assessment of clinical studies included in the evidence review

No studies were identified which were applicable to this review question.

Economic evidence

Included studies
A systematic review of the economic literature was conducted but no economic
studies were identified which were applicable to this review question.
A single economic search was undertaken for all topics included in the scope of this
guideline. Please see supplementary material 2 for details.

Excluded studies
No full-text copies of articles were requested for this review and so there is no
excluded studies list.

Economic model
No economic modelling was undertaken for this review because the committee
agreed that other topics were higher priorities for economic evaluation.

7
 FINAL

Resource impact

Table 2: Unit costs of venous thromboembolism

Resource Unit costs Source
Low weight molecular heparin. 9 day course £107 NICE TA341
Nurses Time to explain administration (10 £6.16 PSSRU 2018
minutes)1
1 Band 5 Nurse excluding qualification costs

Evidence statements
No studies were identified which were applicable to this review question.

The committee’s discussion of the evidence

Interpreting the evidence

The outcomes that matter most

Fatal pulmonary embolism and cardiovascular mortality were selected as critical
outcomes as they are very serious complications of venous thromboembolism (VTE)
that may be prevented with thromboprophylaxis. A follow-up of 6 weeks was selected
for these outcomes because anticoagulant levels, and corresponding risk of VTE,
return to normal within 6 weeks of term pregnancy and this is likely to be reduced
following an abortion occurring in the first or second trimester.
As pharmacological thromboprophylaxis thins the blood, the likelihood of bleeding is
increased; therefore, major bleeding during prophylactic treatment was included as a
critical outcome and clinically relevant minor bleeding was included as an important
outcome.
Symptomatic deep vein thrombosis was selected as an important outcome as it is the
most common form of VTE and non-fatal pulmonary embolism was selected due to
its severity; as above, 6 week follow-up was chosen for both these outcomes. Finally,
patient satisfaction was selected as an important outcome as low-molecular-weight
heparin requires women to self-administer injections.

The quality of the evidence

No evidence was identified about the optimal timing and duration of VTE prophylaxis
for women having an abortion identified as needing pharmacological
thromboprophylaxis.

Benefits and harms

The committee agreed, based on their knowledge and expertise, that a minimum of 7
days of low-molecular-weight heparin for women having an abortion identified as
needing pharmacological thromboprophylaxis would reduce incidence of VTE in this
population. This is in line with recommendations from the NICE guideline NG89 on
hospital-acquired VTE in over 16s (NICE 2018).
The committee were not able to make recommendations about who requires
thromboprophylaxis as risk factors for VTE were not considered as part of this review
question. The risk assessment recommended in NG89 is based on evidence from
term pregnancies and coagulation factors increase during pregnancy. As the vast
majority of abortions occur at lower gestational ages, coagulation factors and

8
 FINAL

corresponding VTE risk will be lower for women having an abortion compared with
women carrying a pregnancy to term. Therefore, as coagulation factors are not
included in the assessment of risk, the committee were concerned that identifying
women having an abortion as requiring thromboprophylaxis based on a risk
assessment for term pregnancies will overestimate risk and may result in
overtreatment with thromboprophylaxis. Further, the NICE VTE guideline only covers
women who are admitted to hospital, who are likely to be less mobile than women
who have had an abortion with no complications. Therefore, the committee, based on
their expertise and comments from stakeholders, did not think it was appropriate to
include a cross-reference to this guidance.
The committee agreed that women identified at high risk of thrombosis might need to
start thromboprophylaxis before the abortion in order to reduce risk of VTE whilst the
abortion is being arranged, particularly if delays are anticipated, and that a longer
duration of thromboprophylaxis may be needed in this population. The committee
noted that these recommendations are in line with the antenatal and postnatal risk
assessment tools for obstetric thromboprophylaxis from the Royal College of
Obstetricians and Gynaecologists (2015), which recommend both antenatal
thromboprophylaxis and a longer duration of postnatal thromboprophylaxis in women
identified as high risk of VTE compared with intermediate risk.

Despite the limited evidence, the committee decided to prioritise other areas
addressed by the guideline for future research and therefore made no research
recommendations regarding thromboprophylaxis in women undergoing an abortion.

Cost effectiveness and resource use

A systematic review of the economic literature was conducted but no relevant studies
were identified which were applicable to this review question.
The committee discussed that women who have not previously administered low-
molecular-weight heparin (LMWH) will need to be taught how to self-administer
LMWH and normally give themselves the first injection under supervision. For women
requiring thromboprophylaxis who have gone home to expel the pregnancy, this
would mean returning to the clinic for an additional appointment after the pregnancy
has been expelled. For those admitted to a clinical setting, they will need to remain in
the service for 4 to 8 hours after the abortion to allow bleeding to subside before
LMWH is administered, which may be longer than normal for an uncomplicated
abortion.
These recommendations are in line with recommendations in the NICE VTE
guideline but cover all women having an abortion who are at risk of thrombosis,
rather than just those admitted to hospital. Therefore, there will be an increase in the
number of women receiving prophylaxis. There will be increased costs and resource
use associated with the increased use of low-molecular-weight heparin (LMWH) and
dispensing this to women, training required to enable administration of LMWH and
additional appointments or longer stays in services. The size of this increase will
depend on current local practice and the number of women who are identified at risk
of thrombosis. These costs will be partially offset by a reduction in the incidence of
VTE but the savings associated with this may be small as VTE is a rare event.

Other considerations
The committee discussed that the optimal duration of VTE prophylaxis will be
affected by how long it take for clotting factors to return to normal after an abortion;
however, this was not considered as part of this review question.

9
 FINAL

References
No studies were identified which were applicable to this review question.

NICE 2018
National Institute for Health and Care Excellence. (2018). Venous thromboembolism
in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary
embolism (NG89).

RCOG 2015

10
 FINAL

Royal College of Obstetricians and

Gynaecologists (2015). Reducing the
Risk of Venous Thromboembolism
during Pregnancy and the Puerperium.
Green-top Guideline No. 37a. London:
RCOG Press Appendices
Appendix A – Review protocols
Review protocol for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis?
Field (based on PRISMA-P Content
Review question in SCOPE In women who are undergoing a termination of
pregnancy, and who are identified as requiring
thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis?
Review question in guideline In women who are undergoing a termination of
pregnancy up to 24 weeks’ gestation, and who are
identified as requiring pharmacological
thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis?
Type of review question Intervention
Objective of the review To determine the optimal duration and timing of
pharmacological thromboprophylaxis for women
having a termination of pregnancy up to 24 weeks’
gestation who are at risk of VTE.
Eligibility criteria – population Women who are having a surgical or medical
termination of pregnancy up to 24 weeks’ gestation
and have been identified as requiring pharmacological
thromboprophylaxis

Exclusions:
- No indirect evidence will be considered
Eligibility criteria – intervention(s • Low molecular weight heparin
• Direct oral anti coagulants
Eligibility criteria – comparator(s) Comparisons:
Any comparisons of 1-4 will be included:
1. Low molecular weight heparin started at time A for
duration A
2. Low molecular weight heparin started at time A for
duration B
3. Low molecular weight heparin started at time B for
duration A
4. Low molecular weight heparin started at time B for
duration B

11
FINAL

Field (based on PRISMA-P Content

5. Low molecular weight heparin (any start time and
duration) versus direct oral anti coagulants (any
start time and duration)
Outcomes and prioritisation Critical outcomes:
• Cardiovascular mortality within 6 weeks of
termination
• Major bleeding for the duration of the LMWH (as
defined by the International Society on Thrombosis
and Haemostasis bleeding
scale:https://www.wikidoc.org/index.php/Internationa
l_Society_on_Thrombosis_and_Haemostasis_bleedi
ng_scale)
• Fatal pulmonary embolism within 6 weeks of
termination

Important outcomes:
• Symptomatic deep vein thrombosis within 6 weeks
of termination
• Pulmonary embolism within 6 weeks of termination
• Clinically relevant minor bleeding for the duration of
LMWH (as defined by the International Society on
Thrombosis and Haemostasis bleeding scale)
• Patient satisfaction
Eligibility criteria – study design - Systematic reviews of RCTs
- RCTs
- If insufficient RCTs: comparative prospective
cohort studies with n≥100 per arm
- If insufficient comparative prospective cohort
studies: comparative retrospective cohort studies
with n≥100 per arm
Other inclusion exclusion criteria Inclusion:
- English-language
Proposed sensitivity/sub-group Stratified analyses based on the following sub-groups
analysis, or meta-regression of women, where possible:
Medical conditions:
- Complex pre-existing medical conditions
- No complex pre-existing medical conditions
Type of termination:
- Surgical
- Medical
Gestation:
- ≤ 10+0 weeks
- 10+1 to 13+6 weeks
- > 14+0 to 24+0 weeks
Selection process – duplicate Dual weeding will not be performed for this question
screening/selection/analysis Sifting, data extraction, appraisal of methodological
quality and GRADE assessment will be performed by
the systematic reviewer.
Quality control will be performed by the senior
systematic reviewer.
Dual data extraction will not be performed for this
question.

12
FINAL

Field (based on PRISMA-P Content

Data management (software) Pairwise meta-analyses will be performed using
Cochrane Review Manager (RevMan5).
‘GRADEpro’ will be used to assess the quality of
evidence for each outcome.
NGA STAR software will be used for study sifting, data
extraction, recording quality assessment using
checklists and generating bibliographies/citations,
Information sources – databases Sources to be searched: Medline, Medline In-Process,
and dates CCTR, CDSR, DARE, HTA, Embase
Limits (e.g. date, study design):
Apply standard animal/non-English language
exclusion
Dates: from 1995
Only studies conducted from 1995 onwards were
considered for this review question, as low molecular
weight heparin was not available until 1995 and the
first direct oral anti coagulants were approved in 2008.
Identify if an update Not an update
Author contacts For details please see the guideline in development
web site
Highlight if amendment to For details please see section 4.5 of Developing NICE
previous protocol guidelines: the manual
Search strategy – for one For details please see appendix B
database
Data collection process – A standardised evidence table format will be used, and
forms/duplicate published as appendix D (clinical evidence tables) or
H (economic evidence tables).
Data items – define all variables For details please see evidence tables in appendix D
to be collected (clinical evidence tables) or H (economic evidence
tables).
Methods for assessing bias at Standard study checklists will be used to critically
outcome/study level appraise individual studies. For details please see
section 6.2 of Developing NICE guidelines: the manual
Appraisal of methodological quality:
The methodological quality of each study will be
assessed using an appropriate checklist:
• RoBIS for systematic reviews
• Cochrane risk of bias tool for RCTs
• Newcastle-Ottawa scale for non-randomised studies
The risk of bias across all available evidence will be
evaluated for each outcome using an adaptation of the
‘Grading of Recommendations Assessment,
Development and Evaluation (GRADE) toolbox’
developed by the international GRADE working group
http://www.gradeworkinggroup.org/
Criteria for quantitative synthesis For details please see section 6.4 of Developing NICE
(where suitable) guidelines: the manual
Methods for analysis – combining Synthesis of data:
studies and exploring Pairwise meta-analysis will be conducted where
(in)consistency appropriate for all other outcomes.
When meta-analysing continuous data, change scores
will be pooled in preference to final scores.

13
FINAL

Field (based on PRISMA-P Content

For details regarding inconsistency, please see the
methods chapter
Minimally important differences:
For cardiovascular mortality, major bleeding and fatal
pulmonary embolism, statistical significance will be
used as an MID.
All other outcomes default values will be used of: 0.8
and 1.25 for relative risks which will be calculated for
all dichotomous outcomes; 0.5 times SD (of the control
group) for continuous outcomes
Meta-bias assessment – For details please see section 6.2 of Developing NICE
publication bias, selective guidelines: the manual.
reporting bias If sufficient relevant RCT evidence is available,
publication bias will be explored using RevMan
software to examine funnel plots.
Assessment of confidence in For details please see sections 6.4 and 9.1 of
cumulative evidence Developing NICE guidelines: the manual
Rationale/context – Current For details please see the introduction to the evidence
management review.
Describe contributions of authors A multidisciplinary committee developed the guideline.
and guarantor The committee was convened by The National
Guideline Alliance and chaired by Professor Iain
Cameron in line with section 3 of Developing NICE
guidelines: the manual.
Staff from The National Guideline Alliance will
undertake systematic literature searches, appraise the
evidence, conduct meta-analysis and cost-
effectiveness analysis where appropriate, and draft the
guideline in collaboration with the committee. For
details please see the methods chapter.
Sources of funding/support The National Guideline Alliance is funded by NICE and
hosted by the Royal College of Obstetricians and
Gynaecologists
Name of sponsor The National Guideline Alliance is funded by NICE and
hosted by the Royal College of Obstetricians and
Gynaecologists
Roles of sponsor NICE funds The National Guideline Alliance to develop
guidelines for those working in the NHS, public health,
and social care in England
PROSPERO registration number Not registered
GRADE: Grading of Recommendations Assessment, Development and Evaluation; LMWH: low-
molecular-weight heparin; MID: minimally important difference; NHS: National Health Service; NICE:
National Institute for Health and Care Excellence; NGA: National Guideline Alliance; RCT: randomised
controlled trial; RoBIS: risk of bias in systematic reviews; SD: standard deviation; VTE: venous
thromboembolism

14
 FINAL

Appendix B – Literature search strategies

Literature search strategy for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and duration
of VTE prophylaxis?
The search for this topic was last run on 18th October 2018. It was agreed to be unnecessary
to undertake a re-run for this topic in November 2018 given that the original search was from
only a month earlier.

Database: Medline & Embase (Multifile)

Last searched on Embase Classic+Embase 1947 to 2018 October 17, Ovid MEDLINE(R)
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily and Ovid MEDLINE(R) 1946 to October 17, 2018
Date of last search: 18th October 2018
# Searches
1 exp abortion/ use emczd
2 exp pregnancy termination/ use emczd
3 exp Abortion, Induced/ use ppez
4 Abortion Applicants/ use ppez
5 exp Abortion, Spontaneous/ use ppez
6 exp Abortion, Criminal/ use ppez
7 Aborted fetus/ use ppez
8 fetus death/ use emczd
9 abortion.mp.
10 (abort$ or postabort$ or preabort$).tw.
11 ((f?etal$ or f?etus$ or gestat$ or midtrimester$ or pregnan$ or prenatal$ or pre
natal$ or trimester$) and terminat$).tw.
12 ((f?etal$ or f?etus$) adj loss$).tw.
13 ((gestat$ or midtrimester$ or pregnan$ or prenatal$ or pre natal$ or trimester$)
adj3 loss$).tw.
14 (((elective$ or threaten$ or voluntar$) adj3 interrupt$) and pregnan$).tw.
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16 exp Heparin, Low-Molecular-Weight/ use ppez
17 exp low molecular weight heparin/ use emczd
18 (lmwh or lmwhs).ti,ab.
19 ((LMW$ or weight$ or dose$ or molecular$) adj heparin$).ti,ab.
20 (bemiparin$ or certoparin$ or dalteparin$ or enoxaparin$ or fragmin$ or
nadroparin$ or parnaparin$ or reviparin$ or tinzaparin$).ti,ab.
21 16 or 17 or 18 or 19 or 20
22 15 and 21
23 (direct$ adj oral adj (anticoagulant$ or anti-coagulant$)).ti,ab.
24 DOAC$.ti,ab.
25 (apixaban/ or dabigatran/ or edoxaban/ or rivaroxaban/) use emczd
26 (apixiban$ or dabigatran$ or rivaroxaban$ or edoxaban$).ti,ab.
27 23 or 24 or 25 or 26
28 15 and 27

15
FINAL

# Searches
29 22 or 28
30 limit 29 to english language
31 limit 30 to yr="1995 -Current"
32 remove duplicates from 31
33 letter/
34 editorial/
35 news/
36 exp historical article/
37 Anecdotes as Topic/
38 comment/
39 case report/
40 (letter or comment*).ti.
41 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40
42 randomized controlled trial/ or random*.ti,ab.
43 41 not 42
44 animals/ not humans/
45 exp Animals, Laboratory/
46 exp Animal Experimentation/
47 exp Models, Animal/
48 exp Rodentia/
49 (rat or rats or mouse or mice).ti.
50 43 or 44 or 45 or 46 or 47 or 48 or 49
51 letter.pt. or letter/
52 note.pt.
53 editorial.pt.
54 case report/ or case study/
55 (letter or comment*).ti.
56 51 or 52 or 53 or 54 or 55
57 randomized controlled trial/ or random*.ti,ab.
58 56 not 57
59 animal/ not human/
60 nonhuman/
61 exp Animal Experiment/
62 exp Experimental Animal/
63 animal model/
64 exp Rodent/
65 (rat or rats or mouse or mice).ti.
66 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65
67 50 use ppez
68 66 use emczd
69 67 or 68
70 32 and 69
71 32 not 70

Database: Cochrane Library via Wiley Online

Date of last search: 18th October 2018
16
FINAL

# Searches
#1 MeSH descriptor: [Abortion, Induced] explode all trees
#2 MeSH descriptor: [Abortion Applicants] explode all trees
#3 MeSH descriptor: [Abortion, Spontaneous] explode all trees
#4 MeSH descriptor: [Abortion, Criminal] explode all trees
#5 MeSH descriptor: [Aborted Fetus] explode all trees
#6 "abortion":ti,ab,kw (Word variations have been searched)
#7 (abort* or postabort* or preabort*):ti,ab,kw (Word variations have been searched)
#8 ((fetal* or fetus* or foetal* or foetus* or gestat* or midtrimester* or pregnan* or
prenatal* or pre natal* or trimester*) and terminat*):ti,ab,kw (Word variations have
been searched)
#9 ((fetal* or fetus* or foetal* or foetus*) next loss*):ti,ab,kw (Word variations have
been searched)
#10 ((gestat* or midtrimester* or pregnan* or prenatal* or pre natal* or trimester*)
near/3 loss*):ti,ab,kw (Word variations have been searched)
#11 (((elective* or threaten* or voluntar*) near/3 interrupt*) and pregnan*):ti,ab,kw
(Word variations have been searched)
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 MeSH descriptor: [Heparin, Low-Molecular-Weight] explode all trees
#14 (lmwh or lmwhs):ti,ab,kw (Word variations have been searched)
#15 ((LMW* or weight* or dose* or molecular*) next heparin*):ti,ab,kw (Word variations
have been searched)
#16 (bemiparin* or certoparin* or dalteparin* or enoxaparin* or fragmin* or nadroparin*
or parnaparin* or reviparin* or tinzaparin*):ti,ab,kw (Word variations have been
searched)
#17 (direct* next oral next (anticoagulant* or anti-coagulant*)):ti,ab,kw (Word variations
have been searched)
#18 DOAC*:ti,ab,kw (Word variations have been searched)
#19 (apixiban* or dabigatran* or rivaroxaban* or edoxaban*):ti,ab,kw (Word variations
have been searched)
#20 #13 or #14 or #15 or #16 or #17 or #18 or #19
#21 #12 and #20

17
 FINAL

Appendix C – Clinical evidence study selection

Clinical evidence study selection for review question: In women who are
undergoing an abortion up to 24 weeks’ gestation, and who are identified as
requiring pharmacological thromboprophylaxis, what is the optimal timing and
duration of VTE prophylaxis?

Figure 1: Study selection flow chart

Titles and abstracts

identified, N= 1451

Full copies retrieved Excluded, N= 1449

and assessed for (Not relevant population,
eligibility, N= 2 design, intervention,
comparison, outcomes,
unable to retrieve)

Studies included in Publications excluded

review, N= 0 from review, N=2
(Refer to excluded
studies list)

18
 FINAL

Appendix D – Clinical evidence tables

Clinical evidence tables for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and duration
of VTE prophylaxis?
No studies were identified which were applicable to this review question.

Appendix E – Forest plots

Forest plots for review question: In women who are undergoing an abortion up to
24 weeks’ gestation, and who are identified as requiring pharmacological
thromboprophylaxis, what is the optimal timing and duration of VTE
prophylaxis?
No studies were identified which were applicable to this review question.

Appendix F – GRADE tables

GRADE tables for review question: In women who are undergoing an abortion up
to 24 weeks’ gestation, and who are identified as requiring pharmacological
thromboprophylaxis, what is the optimal timing and duration of VTE
prophylaxis?
No studies were identified which were applicable to this review question.

Appendix G – Economic evidence study selection

Economic evidence for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and duration
of VTE prophylaxis?
No economic evidence was identified which was applicable to this review question.

Appendix H – Economic evidence tables

Economic evidence tables for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and duration
of VTE prophylaxis?
No economic evidence was identified which was applicable to this review question.

Appendix I –Economic evidence profiles

Economic evidence profiles for review question: In women who are undergoing
an abortion up to 24 weeks’ gestation, and who are identified as requiring

19
 FINAL

pharmacological thromboprophylaxis, what is the optimal timing and duration

of VTE prophylaxis?
No economic evidence was identified which was applicable to this review question.

Appendix J –Economic analysis

Economic analysis for review question: In women who are undergoing an
abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and duration
of VTE prophylaxis?
No economic analysis was conducted for this review question.

20
 FINAL

Appendix K – Excluded studies

Excluded studies for review question: In women who are undergoing an abortion
up to 24 weeks’ gestation, and who are identified as requiring pharmacological
thromboprophylaxis, what is the optimal timing and duration of VTE
prophylaxis?

Clinical studies
Study Reason for Exclusion
Kaneshiro, B., Tschann, M., Jensen, J., Bednarek, P., Texeira, R., Comparison not in PICO
Edelman, A., Blood loss at the time of surgical abortion up to 14
weeks in anticoagulated patients: a case series, Contraception, 96,
14-18, 2017
van Eerden, L., de Groot, C. J. M., Zeeman, G. G., Page- Population not in PICO:
Christiaens, G. C. M., Pajkrt, E., Duvekot, J. J., Vandenbussche, F. Pregnant women who had
P., Oei, S. G., Scheepers, H. C. J., van Eyck, J., Middeldorp, J. M., had a previous abortion due
Bolte, A. C., Subsequent pregnancy outcome after mid-trimester to pre-eclampsia
termination of pregnancy for preeclampsia, Australian and New
Zealand Journal of Obstetrics and Gynaecology, 58, 204-209, 2018
PICO: population, intervention, comparison and outcome

Economic studies
No economic evidence was identified for this review. See supplementary material X for
further information.

21
 FINAL

Appendix L – Research recommendations

Research recommendations for review question: In women who are undergoing
an abortion up to 24 weeks’ gestation, and who are identified as requiring
pharmacological thromboprophylaxis, what is the optimal timing and duration
of VTE prophylaxis?
No research recommendations were made for this review question.

22